Details of the Drug Pharmacogenomic Perturbation Atlas

Fosinopril Drug Info

Acecor; Fosenopril; Monopril; Staril; FOSINOPRIL SODIUM; Fosinopril (INN); Fosinopril [INN:BAN]; Monopril (TN); SQ-28555; SQ-28,555; Fosinopril, (1(S*(R*)),2 alpha,4 beta)-Isomer; (2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid; (2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid; (4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline; (4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline; 4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid

Therapeutic Class

Antihypertensive Agents

Cross-matching ID

PubChem CID

55891

ChEBI ID

CHEMBL5163

CAS Number

CAS 98048-97-6

TTD Drug ID

D0X8KY

VARIDT Drug ID

DR00701

ACDINA Drug ID

D00293

General Information of Drug (ID: DM9NJ52)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Homologous recombination	1.81	1.52e-1	35/41 (85.37%)	RAD51;SEM1;RAD51C;...
IL-17 signaling pathway	1.76	1.23e-1	84/94 (89.36%)	CXCL8;CCL20;LCN2;...
Pancreatic cancer	1.75	1.02e-1	75/76 (98.68%)	STAT3;TGFBR2;MAPK1;...
DNA replication	1.72	9.08e-2	34/36 (94.44%)	MCM6;RFC2;POLE3;...
Pentose and glucuronate interconversions	1.72	7.73e-2	17/34 (50%)	SORD;DCXR;UGT2B28;...
Porphyrin and chlorophyll metabolism	1.67	1.23e-1	23/43 (53.49%)	UGT2B28;HMBS;ALAS2;...
Mismatch repair	1.66	1.17e-1	22/23 (95.65%)	RFC2;MSH2;RPA2;...
N-Glycan biosynthesis	1.66	1.05e-1	38/50 (76%)	ALG6;B4GALT1;FUT8;...
Valine, leucine and isoleucine degradation	1.64	1.17e-1	42/48 (87.5%)	DLD;ABAT;PCCA;...
Prostate cancer	1.63	1.11e-1	93/97 (95.88%)	NKX3-1;TMPRSS2;MAPK1;...
Fc gamma R-mediated phagocytosis	1.60	1.45e-1	79/97 (81.44%)	MAPK1;ACTR2;ARPC5L;...
Acute myeloid leukemia	1.58	1.47e-1	66/67 (98.51%)	STAT3;MAPK1;RUNX1;...
Nucleotide excision repair	1.56	1.60e-1	40/47 (85.11%)	RAD23B;GTF2H4;RFC2;...
Chemokine signaling pathway	1.56	1.52e-1	163/192 (84.9%)	CXCL8;STAT3;CCL20;...
Glycine, serine and threonine metabolism	1.56	1.45e-1	31/40 (77.5%)	DLD;ALAS2;GCAT;...
Ubiquinone and other terpenoid-quinone biosynthesis	1.54	1.57e-1	9/11 (81.82%)	COQ2;NQO1;GGCX;...
Glycolysis / Gluconeogenesis	1.52	1.76e-1	56/67 (83.58%)	DLD;PFKP;ENO2;...
Mucin type O-glycan biosynthesis	1.52	1.66e-1	20/36 (55.56%)	GALNT3;ST3GAL1;GALNT10;...
Ascorbate and aldarate metabolism	1.51	1.75e-1	15/30 (50%)	UGT2B28;UGT2B17;KL;...
Basal transcription factors	1.51	1.69e-1	37/45 (82.22%)	TAF15;GTF2H4;GTF2I;...
Phosphonate and phosphinate metabolism	1.50	1.65e-1	5/6 (83.33%)	CHPT1;CEPT1
Kaposi sarcoma-associated herpesvirus infection	1.50	1.64e-1	172/193 (89.12%)	CXCL8;STAT3;MAPK1;...
Bladder cancer	1.48	1.81e-1	40/41 (97.56%)	CXCL8;MAPK1;MMP9;...
Peroxisome	1.48	1.81e-1	72/82 (87.8%)	ECI2;SLC27A2;ACSL3;...
Propanoate metabolism	1.46	2.05e-1	30/34 (88.24%)	DLD;ABAT;PCCA;...
Glycosaminoglycan biosynthesis	1.45	2.07e-1	40/58 (68.97%)	CSGALNACT1;CHST15;ST3GAL1;...
B cell receptor signaling pathway	1.45	2.04e-1	71/81 (87.65%)	MAPK1;BLNK;PPP3CA;...
Glutathione metabolism	1.44	2.06e-1	43/57 (75.44%)	RRM2;ODC1;GPX1;...
Renin-angiotensin system	1.38	2.37e-1	20/23 (86.96%)	KLK2;CPA3;AGT;...
Natural killer cell mediated cytotoxicity	1.36	2.37e-1	99/131 (75.57%)	MAPK1;SHC1;PPP3CA;...
Sulfur metabolism	-1.30	3.10e-1	9/10 (90%)	MPST;PAPSS2
Pantothenate and CoA biosynthesis	-1.30	3.16e-1	14/21 (66.67%)	ENPP1;COASY;BCAT2;...
Thyroid hormone signaling pathway	-1.30	3.16e-1	112/121 (92.56%)	ATP1A3;HDAC1;TSC2;...
Autophagy	-1.31	3.18e-1	113/169 (66.86%)	IGBP1;NRBF2;MTMR3;...
AMPK signaling pathway	-1.31	3.15e-1	106/120 (88.33%)	RAB2A;ADIPOQ;INS;...
PPAR signaling pathway	-1.32	3.17e-1	66/74 (89.19%)	ACSL4;PLIN2;LPL;...
Vitamin digestion and absorption	-1.34	3.11e-1	17/24 (70.83%)	ABCC1;PNLIP;SLC5A6;...
Dilated cardiomyopathy	-1.34	3.15e-1	86/96 (89.58%)	DMD;ITGB8;DES;...
Allograft rejection	-1.36	2.71e-1	32/38 (84.21%)	CD80;HLA-DRB1;HLA-DPA1;...
Regulation of lipolysis in adipocytes	-1.37	2.78e-1	52/55 (94.55%)	AKT3;AQP7;LIPE;...
Th1 and Th2 cell differentiation	-1.37	2.84e-1	80/92 (86.96%)	STAT4;CD4;HLA-DRB1;...
Phosphatidylinositol signaling system	-1.38	2.87e-1	82/97 (84.54%)	PIP4K2A;INPP5E;MTMR3;...
Cytosolic DNA-sensing pathway	-1.38	2.90e-1	52/63 (82.54%)	TBK1;IL33;NFKBIA;...
Toll-like receptor signaling pathway	-1.38	3.03e-1	94/104 (90.38%)	MAP2K7;CD86;TBK1;...
Autoimmune thyroid disease	-1.44	2.18e-1	46/53 (86.79%)	CD80;HLA-DRB1;HLA-DPA1;...
Phagosome	-1.45	2.15e-1	118/152 (77.63%)	ITGB5;ATP6V0D1;NCF2;...
Systemic lupus erythematosus	-1.47	1.93e-1	45/135 (33.33%)	CD86;HLA-DPB1;C1QB;...
Basal cell carcinoma	-1.48	1.87e-1	41/63 (65.08%)	DVL1;AXIN1;APC;...
Fat digestion and absorption	-1.49	1.94e-1	35/43 (81.4%)	PNLIP;AGPAT1;CLPS;...
Primary immunodeficiency	-1.50	1.98e-1	33/38 (86.84%)	CD8B;ZAP70;IL7R;...
Thyroid cancer	-1.50	2.04e-1	36/37 (97.3%)	GADD45A;NTRK1;TFG;...
Cardiac muscle contraction	-1.52	1.99e-1	64/87 (73.56%)	CACNG2;TRDN;MYL3;...
Wnt signaling pathway	-1.52	2.20e-1	124/166 (74.7%)	CAMK2G;FBXW11;MMP7;...
Malaria	-1.53	2.22e-1	44/50 (88%)	THBS3;CD36;CCL2;...
Cell adhesion molecules	-1.54	2.35e-1	118/148 (79.73%)	CD80;CD99;MPZL1;...
ECM-receptor interaction	-1.54	2.65e-1	80/88 (90.91%)	SDC4;ITGA2B;COL6A1;...
Arrhythmogenic right ventricular cardiomyopathy	-1.59	1.98e-1	70/77 (90.91%)	ITGB1;SGCG;ITGA4;...
Cholesterol metabolism	-1.61	2.01e-1	44/50 (88%)	LIPG;ANGPTL4;LCAT;...
Pancreatic secretion	-1.63	2.11e-1	87/102 (85.29%)	CELA2B;PRSS1;TRPC1;...
Notch signaling pathway	-1.66	2.56e-1	49/59 (83.05%)	KAT2A;DVL1;CTBP1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Ewing sarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
SK-ES-1	CVCL_0627	Homo sapiens	1.11uM - 10uM	24H

Brain

Glioma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
GI-1	CVCL_1230	Homo sapiens	1.11uM - 10uM	24H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-468	CVCL_0419	Homo sapiens	1.11uM - 10uM	24H

Breast ductal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
T-47D	CVCL_0553	Homo sapiens	1.11uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

SNU-407	CVCL_5004	Homo sapiens	1.11uM - 10uM	24H

Endometrium

Endometrial adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
HEC-108	CVCL_2926	Homo sapiens	1.11uM - 10uM	24H

HEC-1-A	CVCL_0293	Homo sapiens	1.11uM - 10uM	24H

HEC-251	CVCL_2928	Homo sapiens	1.11uM - 10uM	24H

HEC-265	CVCL_2929	Homo sapiens	1.11uM - 10uM	24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CJM	CVCL_U797	Homo sapiens	1.11uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
JHH-5	CVCL_1320	Homo sapiens	1.11uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
A549	CVCL_0023	Homo sapiens	10uM	6H

NCI-H1573	CVCL_1483	Homo sapiens	1.11uM - 10uM	24H

NCI-H838	CVCL_1594	Homo sapiens	1.11uM - 10uM	24H

Lung squamous cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
BEN	CVCL_1081	Homo sapiens	1.11uM - 10uM	24H

HCC95	CVCL_1276	Homo sapiens	1.11uM - 10uM	24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Muscle

Rhabdomyosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-204	CVCL_0134	Homo sapiens	1.11uM - 10uM	24H

Ovary

Ovarian clear cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
OVTOKO	CVCL_3114	Homo sapiens	1.11uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
22Rv1	CVCL_1045	Homo sapiens	1.11uM - 10uM	24H

PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H

IGR-37	CVCL_1303	Homo sapiens	1.11uM - 10uM	24H

Mel-HO	CVCL_1402	Homo sapiens	1.11uM - 10uM	24H

SH-4	CVCL_1692	Homo sapiens	1.11uM - 10uM	24H

Urinary bladder

Bladder carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
BC-3C	CVCL_1079	Homo sapiens	1.11uM - 10uM	24H

Bladder transitional cell carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
CAL-29	CVCL_1109	Homo sapiens	1.11uM - 10uM	24H